GET DAILY SIGNALSCabaletta Bio (CABA) Q3 Results: Narrower Per-Share Loss Amid Higher Spending
Key Takeaways
- Cabaletta Bio (CABA) reported a net loss of $53.05 million for the third quarter ended September 30, 2026, compared with $44.87 million in the same period a year earlier.
- Net loss per share narrowed to $0.28 from $0.44 a year ago, topping the analyst consensus estimate of roughly $0.31 per share.
- For the first nine months of 2026, the net loss was $147.59 million (about $0.98 per share), versus $125.94 million (about $1.75 per share) in the prior-year period.
- The wider total net loss reflects higher spending as the clinical-stage biotech advances its pipeline of engineered T cell therapies for autoimmune diseases.
- Following the report, analysts remained active: Morgan Stanley kept a Buy rating with a $13.00 target, while H.C. Wainwright reiterated a Buy rating and a $16.00 target.
- For additional detail, you can review Cabaletta Bio's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To broaden your research across the market, explore Trending AI Robots for AI-driven trading ideas.
Earnings Context and Why It Matters
Cabaletta Bio is a clinical-stage biotechnology company focused on engineered T cell therapies that aim to deliver deep, potentially curative responses after a single administration for patients with autoimmune diseases. As a pre-revenue firm, its quarterly reports draw attention mainly for cash burn rates, operating expense patterns, and signs of clinical advancement rather than revenue figures. The loss amount serves as a useful gauge of how effectively management is allocating resources to push forward its lead candidate, resecabtagene autoleucel (rese-cel), a CD19-targeted CAR T therapy. In a sector where sentiment can shift quickly, each quarter’s spending details and any pipeline updates often influence share movement.
Reported Results
For the third quarter ended September 30, 2026, CABA posted a net loss of $53.05 million, an increase from the $44.87 million loss in the year-ago quarter. On a per-share basis, the loss improved to $0.28 from $0.44, helped by a larger share count. This result beat the consensus estimate of about $0.31 per share by roughly $0.03. Over the first nine months of 2026, the company recorded a net loss of $147.59 million (approximately $0.98 per share), up from $125.94 million (about $1.75 per share) in the comparable prior period. Cash, cash equivalents, and marketable securities stood at roughly $299 million at quarter end, an important metric given ongoing research and development outlays. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
CABA shares have shown significant volatility, in line with the stock’s high beta of roughly 3.5 and its position well below the 52-week high of $4.23. The modest per-share beat did not fully ease concerns around rising cash burn and the extended timeline to potential commercialization. Analyst views stayed generally positive despite the wider total loss: Morgan Stanley held its Buy rating and $13.00 price target, while H.C. Wainwright kept a Buy rating with a $16.00 target. Other firms have adopted a more measured stance on near-term upside. This reaction highlights that, for pre-revenue biotechs, upcoming clinical milestones and cash runway often weigh more heavily than any single quarter’s loss number.
Forward Outlook and Key Factors to Monitor
Looking ahead, attention will center on the pace of clinical progress and expense management against the roughly $299 million cash position. The lead program, rese-cel, continues to anchor the investment case, so updates on enrollment, safety, or efficacy in autoimmune settings will likely shape sentiment most directly.
Cost control remains worth watching. With research and development outlays rising, the quarterly cash consumption rate will influence views on runway length and any future financing considerations.
Sector conditions also play a role. Biotechnology valuations continue to respond to interest rates, regulatory shifts, and overall appetite for clinical-stage risk. Although the latest quarter showed a narrower per-share loss than expected, longer-term performance will depend more on data milestones than quarterly results alone.
Leveraging AI Tools in Biotech Research
In my analysis of names like CABA, I often turn to Tickeron’s AI Screener to quickly scan for comparable companies, review technical patterns, and track momentum shifts across the biotech space. It helps surface ideas and monitor how individual stocks stack up against peers without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CABA turns negative, indicating new downward trend
CABA saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Indicator exited the oversold zone, 24 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology
Advertisement